培门冬酶治疗儿童急性淋巴细胞白血病的近期疗效及对患儿不良反应的影响

Abstract
Figure/Table
References
Related Citation (1)

Download: PDF (1869 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the short-term efficacy of pegaspargase in the treatment of children with acute lymphoblastic leukemia and its effect on the adverse reactions of children. Methods In this study, 86 children with ALL who were scheduled to undergo chemotherapy in our hospital from January 2018 to January 2021 were prospectively selected as the research objects, and all the children were randomly divided into the control group and the study group, with 43 cases in each group, The control group received vincristine + daunorubicin + L-asparaginase + prednisone combined chemotherapy (VDLP scheme); The study group received vincristine + daunorubicin + domestic pegaspargase + prednisone combined chemotherapy (VDPAP scheme). Hemoglobin, percentage of immature cells, platelet count, coagulation function, liver and kidney function were compared between the two groups. The clinical remission rate, average length of hospital stay, number of medication and event-free survival rates at 6 months and 1 year of treatment were compared between the two groups. The adverse reactions of the two groups were compared. Results After 3 months of treatment, the percentage of immature cells in the study group was significantly decreased, and the hemoglobin and PLT in control group were significantly increased. Compared with control group, the values of ALT, BUN, PT, APTT and TT in study group were significantly increased, while ALB and FIB were significantly decreased. The clinical remission rate in study group was higher than in control group. The hospitalization time and medication times of study group were significantly less than those of control group, and there was no significant difference in the event-free survival rate between the two groups at 6 months and 1 year of treatment. The number of gastrointestinal reactions, allergic reactions and in study group was significantly higher than that in control group. There was no significant difference in other indicators between the two groups. Conclusion Peaspargase has obvious advantages in the treatment of children with ALL. It can not only greatly reduce the myelosuppression of children with ALL, promote lymphocyte maturation, but also significantly improve the coagulation function and clinical remission rate of children with ALL, and greatly reduce adverse reactions reaction, However, relatively speaking, pegaspargase has a certain effect on liver function, and it is necessary to further improve the treatment method to reduce the damage rate of liver cells.

Key words： childhood acute lymphoblastic leukemia pegaspargase L-asparaginase percentage of immature cells

Received: 07 September 2022

PACS:

R733.7

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Yan
	DAI Li
	HUANG Qian
	CAI Li
	XIAO-LI Yan

Cite this article:

LIU Yan,DAI Li,HUANG Qian等. Short-term efficacy of pegaspargase in the treatment of children with acute lymphoblastic leukemia and its effect on adverse reactions in children[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2023, 20(4): 129-133.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2023/V20/I4/129

[1] 张琳琳. E2 A-PBX1融合基因阳性儿童急性淋巴细胞白血病发病机制及复发相关因素[J]. 国际儿科学杂志, 2018, 45 (10): 776-778+782.
[2] Inaba H, Mullighan CG.Pediatric acute lymphoblastic leukemia[J]. Haematologica, 2020, 105(11): 2524-2539.
[3] Lato MW, Przysucha A, Grosman S, et al.The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia[J]. Int J Mol Sci, 2021, 22(9): 4502.
[4] 林艳艳, 许岩, 李慧. 儿童急性淋巴细胞白血病化学治疗常规药物耐药机制的研究进展[J]. 上海交通大学学报 (医学版) , 2022, 42(2): 211-217.
[5] 李芸蕊, 张磊, 刘阳, 等. 左旋门冬酰胺酶联合化疗治疗急性淋巴细胞白血病儿童对血糖及免疫功能影响的临床研究[J]. 实用癌症杂志, 2021, 36(8): 1386-1390.
[6] 高琴丽, 陈彩, 乐少华, 等. 儿童急性淋巴细胞白血病化疗合并培门冬酶相关胰腺炎临床分析[J]. 中国小儿血液与肿瘤杂志, 2021, 26 (5): 285-288+293.
[7] 占诗贵, 张丽娜, 黄正刚, 等. 左旋门冬酰胺酶和培门冬酶治疗儿童急性淋巴细胞白血病的不良反应研究[J]. 中国药物评价, 2020, 37(1): 50-54.
[8] 顾龙君. 儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)[J].中华儿科杂志, 2006,(05):392-395.
[9] 沈悌、赵永强.血液病诊断及疗效标准(第4版)[M].北京:科学出版社,2018.
[10] Imai K.[Acute lymphoblastic leukemia: pathophysiology and current therapy][J]. Rinsho Ketsueki, 2017, 58(5): 460-470.
[11] 李贝多. 儿童急性淋巴细胞白血病合并血栓栓塞研究进展[J]. 临床儿科杂志, 2022, 40(6): 475-480.
[12] Onciu M.Acute lymphoblastic leukemia[J]. Hematol Oncol Clin North Am, 2009, 23(4): 655-674.
[13] 王治香, 王蔷, 林韧, 等. 强化培门冬酶化学药物治疗方案降低成人费城染色体阴性ALL移植后复发[J]. 中华器官移植杂志, 2021, 42(4): 209-213.
[14] 江华, 顾龙君, 薛惠良, 等. ALL患儿肿瘤细胞的门冬酰胺合成酶活性研究[J]. 中国当代儿科杂志, 2006, 8(4): 272-274.
[15] 林世光, 汤静燕, 潘慈. 66例急性淋巴细胞白血病肝功能异常分析[J]. 临床儿科杂志, 2004, 22(7): 456-457.
[16] 司艳辉, 王洋洋, 李冰, 等. 重组人粒细胞刺激因子联合VDLP方案治疗费城染色体阴性急性淋巴细胞白血病患者的临床效果[J]. 中国当代医药, 2020, 27(4): 96-99.
[17] 侯小瑞, 靳瑞霞, 谢意茹, 等. 培门冬酶对急性淋巴细胞白血病患儿的治疗效果及对凝血功能的影响[J]. 癌症进展, 2020, 18 (17): 1813-1816+1835.
[18] 中国临床肿瘤学会 (CSCO) , 中华医学会血液学分会 (CHS) , 中华儿科血液学分会 (CCHS) . 培门冬酶治疗急性淋巴细胞白血病和恶性淋巴瘤的专家共识[J]. 临床肿瘤学杂志, 2013, 18(3): 256-263.
[19] 林全德, 左文丽, 杜建伟, 等. 含培门冬酶的VDPAP方案治疗儿童急性淋巴细胞白血病临床疗效[C]//中华医学会. 中华医学会第十二次全国血液学学术会议论文集. 北京: 中华医学会, 2012: 22.
[20] 何文谦. 大剂量阿糖胞苷联合培门冬酶在急性淋巴细胞白血病患儿巩固治疗中的应用效果及其安全性[J]. 临床合理用药杂志, 2022, 15(6): 165-167.
[21] 王长爽. 培门冬酶与左旋门冬酰胺酶治疗儿童急性淋巴细胞白血病的疗效及安全性观察[J]. 中国药物与临床, 2021, 21(23): 3871-3873.
[22] 陈力溶, 王西阁, 徐一卓, 等. 两种门冬酰胺酶对儿童急性淋巴细胞白血病诱导缓解治疗中的不良反应的对比研究[J]. 中国小儿血液与肿瘤杂志, 2019, 24 (2): 69-73+79.
[23] 刘桂梅, 王梦川. 急性淋巴细胞白血病患儿应用培门冬酶后发生过敏反应的抢救与护理[J]. 护理实践与研究, 2011, 8(19): 41-42.
[24] 林舒鹏, 宋华, 沈和萍, 等. 急性淋巴细胞白血病患儿中可逆性脑病临床总结[J]. 临床儿科杂志, 2019, 37(5): 326-330.